Federal Contractor Profile
Lovelace Biomedical Research Institute
$39.9M obligated·83 awards·5 agencies·9 NAICS
Federal Contracts
Showing contracts 1–50 of 69 total. Sorted by action date, most recent first. Excludes $0 modifications.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Apr 1, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022F00001 | 541715 | THE CONTRACTOR SHALL PERFORM THE TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMA | $55K |
| Sep 30, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93025D00021 | 541715 | EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES. | $10K |
| Sep 22, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | $2.0M |
| Sep 19, 2025 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40125P00216 | 541380 | SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP). | $7.1M |
| Aug 27, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022F00001 | 541715 | THE CONTRACTOR SHALL PERFORM THE TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMA | $139K |
| Jul 17, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES | $21K |
| Jul 9, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH22P0157 | 511210 | LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR. | $42K |
| Jun 30, 2025 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40119C10161 | 541380 | STUDY OF E-CIGARETTE AEROSOL TOXICITY IN IN VIVO NONCLINICAL MODELS. | $9.8M |
| May 19, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA, MMAB) | $1.7M |
| Sep 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00004 | 541715 | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021 | $133K |
| Sep 17, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $121K |
| Aug 27, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92024P00303 | 541380 | 24-015894 NHLBI POPULATION SCIENCES BRANCH REQUIRES PULMONARY FUNCTION TESTING TO DETERMINE IF THE FLEXIVENT METHOD OF PULMONARY FUNCTION TESTING IS SUITABLE TO BE USED IN A LARGER STUDY. | $17K |
| Aug 19, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00005 | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022 | $48K |
| Aug 14, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | $1.7M |
| Aug 6, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00001 | 541714 | KICK-OFF MEETING FOR THE PHARMACOLOGY STUDIES AND ANIMAL MODEL DEVELOPMENT AND RELATED SERVICES FOR DRUG DEVELOPMENT IDIQ CONTRACT. | $1K |
| Aug 1, 2024 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH22P0157 | 511210 | LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR. | $225K |
| Jul 18, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES | $37K |
| Jun 17, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00001 | 541715 | BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS | $44K |
| Mar 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00001 | 541715 | EVALUATION OF POTENTIAL RESPIRATORY STIMULANT. TO4. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025. | $141K |
| Mar 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00002 | 541715 | RESPIRATORY INTERACTION STUDIES IN RODENTS, ABILITY OF A TEST ARTICLE TO REVERSE THE RESPIRATORY DEPRESSANT EFFECTS OF OPIOIDS. TO5. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025. | $211K |
| Jan 9, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00005 | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022 | $3K |
| Dec 19, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92024F00001 | 541714 | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY - TASK AREA A: CORE ADMINISTRATIVE ACTIVITIES | $11K |
| Nov 15, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95023F00001 | 541715 | CHARACTERIZATION OF SPONTANEOUS OSTEOGENESIS AFTER SURGICAL SEGMENTAL BONE DEFECT IN A LARGE ANIMAL | $192K |
| Sep 29, 2023 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40123F19002 | 541690 | TASK ORDER 2 - EXAMINING THE INFLUENCE OF SYNTHETIC COOLING AGENTS ON CIGARETTE SENSORY AND SUBJECTIVE EFFECTS AND USE BEHAVIOR | $1.3M |
| Sep 29, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95023F00002 | 541715 | EFFICACY AND SAFETY EVALUATION OF LEAD GENE THERAPY CANDIDATE IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT | $1.6M |
| Sep 27, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | $2.0M |
| Sep 27, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00005 | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022 | $380K |
| Sep 27, 2023 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40123F19001 | 541690 | TASK ORDER 1 -TITLE: ARE REDUCTIONS IN BOE, BOPH, AND OTHER HEALTH RISK MARKERS PROPORTIONAL TO REDUCTIONS IN CIGARETTE SMOKING UPON SWITCHING TO ENDS | $3.9M |
| Sep 26, 2023 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40123D00039 | 541690 | AWARD OF FIVE-YEAR IDIQ FOR CTP- ASSESSING TOBACCO-RELATED CLINICAL OUTCOMES AND HUMAN BEHAVIORS IN TOBACCO | $5K |
| Sep 22, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92023F00001 | 541714 | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY | $234K |
| Sep 19, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541715 | NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. PERIOD OF PERFORMANCE SEPTEMBER 28, 2020 - DECEMBER 31, 2021 | $17K |
| Sep 11, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92023P00366 | 541380 | EVALUATION OF AN ASO IN THE MOUSE CIGARETTE SMOKE AND INFLUENZA MODEL | $171K |
| Aug 29, 2023 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40122F19001 | 541690 | CTP-2022-111127 - SALTS | $53K |
| Aug 28, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | $128K |
| Aug 25, 2023 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH22P0157 | 511210 | LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR. | $219K |
| Aug 25, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $169K |
| Aug 3, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95023F00001 | 541715 | CHARACTERIZATION OF SPONTANEOUS OSTEOGENESIS AFTER SURGICAL SEGMENTAL BONE DEFECT IN A LARGE ANIMAL | $194K |
| Aug 2, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES | $20K |
| Jun 28, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023F00001 | 541715 | GUARANTEED MINIMUM | $18K |
| Apr 5, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023F00001 | 541715 | GUARANTEED MINIMUM | $3K |
| Apr 5, 2023 | Department of DefenseFA9451 AFRL RDK | FA945120P0019 | 541380 | COVID-19 THE PURPOSE OF VIDER IS TO UNDERSTAND THE EFFECTIVENESS OF RF DIRECTED ENERGY RADIATION IN REDUCING THE VIABILITY OF VIRAL AEROSOLS WITH THE GOAL OF RAPIDLY DEVELOPING AND DEPLOYING REMEDIATION METHODS FOR SPACES CONTAMINATED WITH SARS-COV-2 | $13K |
| Mar 31, 2023 | Department of DefenseFA9451 AFRL RDK | FA945120P0019 | 541380 | COVID-19 THE PURPOSE OF VIDER IS TO UNDERSTAND THE EFFECTIVENESS OF RF DIRECTED ENERGY RADIATION IN REDUCING THE VIABILITY OF VIRAL AEROSOLS WITH THE GOAL OF RAPIDLY DEVELOPING AND DEPLOYING REMEDIATION METHODS FOR SPACES CONTAMINATED WITH SARS-COV-2 | $10K |
| Dec 16, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92019F00074 | 541714 | THE NHLBI REQUIRES THE GENE THERAPY RESOURCE PROGRAM (GTRP) SUPPORT TRANSLATIONAL GENE THERAPY RESEARCH BY PROVIDING RESOURCES AND SERVICES FROM THREE CORE LABORATORIES: 1.) PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY, 2.) PRECLINICAL VECTOR CORE LABORATORY, 3.) CLINICAL COORDINATING CENTER (CCC), WHICH IS NOT REQUIRED TO HAVE ANY LABORATORY CAPABILITIES. | $48K |
| Sep 28, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541715 | NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. PERIOD OF PERFORMANCE SEPTEMBER 28, 2020 - DECEMBER 31, 2021 | $440K |
| Sep 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50122D00021 | 541714 | LOVELACE BIOMEDICAL RESEARCH INSTITUTE - BASE (BIO) - IDIQ FOR BARDA BIOLOGICAL ANIMAL MODEL AND MCM DEVELOPMENT | $75K |
| Sep 26, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022F00001 | 541714 | GLP REPEAT DOSE TOXICOLOGY STUDY FOR BPL-24910 | $716K |
| Sep 23, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $798K |
| Sep 23, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | $500K |
| Sep 22, 2022 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40122F19001 | 541690 | CTP-2022-111127 - SALTS | $2.1M |
| Sep 20, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00001 | 541715 | ASSESSMENT OF POTENTIAL TREATMENTS FOR DRUG-INDUCED RESPIRATORY DEPRESSION AND OVERDOSE TOXICITY. POP: SEPTEMBER 26, 2022 - MARCH 25, 2023. TASK ORDER 75N95022F00001 (TO1). | $149K |
Get Alerted Before Lovelace Biomedical Research Institute's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start Free